Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBENECID AND COLCHICINE vs BENEMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
Probenecid: Terminal half-life 6-12 hours (dose-dependent; prolonged at higher doses due to saturable tubular secretion). Colchicine: Terminal half-life 20-40 hours (range 9-30 hours in healthy subjects; prolonged in renal impairment up to 50-60 hours).
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Probenecid: hepatic via glucuronidation and oxidation; colchicine: hepatic via CYP3A4 and P-glycoprotein.
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Probenecid: Renal excretion of unchanged drug and metabolites; approx. 75-95% of dose eliminated in urine, with <5% as unchanged probenecid. Colchicine: Primarily fecal excretion (about 65%) via biliary excretion; renal excretion accounts for about 20-30% of elimination, with enterohepatic recirculation.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Probenecid: 85-95% bound to albumin. Colchicine: 30-50% bound to albumin.
Approximately 85-95% bound primarily to albumin
Probenecid: 0.15 L/kg (indicates distribution primarily in extracellular fluid). Colchicine: 2-8 L/kg (large Vd indicating extensive tissue distribution, particularly into leukocytes and other cells).
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
Probenecid: Oral bioavailability nearly complete (approx. 100%) with extensive metabolism. Colchicine: Oral bioavailability 25-50% (first-pass metabolism and P-glycoprotein efflux in gut); bioavailability listed for oral route.
Oral: >90%
GFR 30-50 m L/min: reduce dose to one tablet daily. GFR 10-29 m L/min: one tablet every 2-3 days. GFR <10 m L/min or dialysis: contraindicated.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce colchicine dose by 50%. Child-Pugh C: contraindicated.
No specific guidelines; use with caution in severe hepatic impairment.
Not recommended for pediatric use. For acute gout in adolescents, consider alternative therapy.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
Start at lowest dose (one tablet daily), monitor renal function and for toxicity due to age-related decreased renal function.
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
None.
No FDA black box warning.
Hematologic toxicity (bone marrow suppression), neuromuscular toxicity (especially with renal impairment), severe diarrhea, drug interactions (CYP3A4 and P-gp inhibitors), use caution in elderly and renal/hepatic impairment.
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Hypersensitivity to probenecid or colchicine, severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, concurrent use of P-gp or CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) in patients with renal/hepatic impairment, blood dyscrasias, uric acid kidney stones.
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Limit consumption of high-purine foods (e.g., organ meats, anchovies, sardines, red meat, shellfish) as they can exacerbate gout. Avoid alcohol, particularly beer and liquor, which increase uric acid production and reduce probenecid efficacy. No specific food interaction with colchicine; maintain adequate hydration.
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformations. Probenecid is not teratogenic in animal studies. Second and third trimesters: No evidence of fetal harm from either drug, but insufficient data. Avoid during pregnancy unless benefit outweighs risk.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Colchicine is excreted into human milk in low concentrations; M/P ratio not established. Probenecid is excreted in milk in amounts likely negligible (M/P ratio ~0.5). Both considered compatible with breastfeeding, but monitor infant for diarrhea (colchicine).
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
No specific pharmacokinetic data in pregnancy; however, increased renal clearance and volume of distribution in pregnancy may reduce probenecid and colchicine plasma concentrations. Consider dose adjustment based on clinical response and toxicity monitoring, but no standard recommendations exist.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
Colchicine levels can increase with concurrent use of P-glycoprotein inhibitors (e.g., amiodarone, verapamil, clarithromycin) or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Probenecid can raise plasma concentrations of penicillins, cephalosporins, and indomethacin. Monitor for colchicine toxicity (nausea, diarrhea, myopathy) especially in renal impairment; reduce dose in chronic kidney disease. Probenecid may inhibit renal excretion of drugs and can cause uricosuria, so ensure high fluid intake to prevent urate stones.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of water (at least 8 glasses per day) while taking probenecid.,Colchicine can cause severe diarrhea or vomiting; stop and call your doctor if this occurs.,Avoid alcohol, which can worsen gout and interfere with probenecid's effect.,Do not start new medications (especially antibiotics, antifungal, or heart medications) without consulting your doctor due to drug interactions.,Report unexplained muscle pain, weakness, numbness, or tingling immediately (colchicine myopathy).,Keep this and all medications out of reach of children.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBENECID AND COLCHICINE vs BENEMID, answered by our medical review team.
PROBENECID AND COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.. BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBENECID AND COLCHICINE and BENEMID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBENECID AND COLCHICINE is: One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.. The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBENECID AND COLCHICINE and BENEMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBENECID AND COLCHICINE is classified as Category A/B. First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformatio. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.